Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 2/20 | 0.56 |
| ▸ | ULK1 | O75385 | 2/20 | 0.50 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.39 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7662487 | 0.97 | PAK1 (0.60) | PAK1ULK1IP6K1MAPK8LMNA | |
| SCHEMBL15264144 | 0.95 | PAK1 (0.62) | PAK1ULK1IP6K1MAPK8LMNA | |
| SCHEMBL2789819 | 0.93 | PAK1 (0.51) | PAK1ULK1IP6K1MAPK8AXL | |
| SCHEMBL6797414 | 0.88 | PAK1 (0.47) | PAK1ULK1MAPK8MKNK1AXL | |
| SCHEMBL7068425 | 0.86 | PAK1 (0.46) | PAK1ULK1MAPK8MKNK2FLT3 | |
| SCHEMBL6796018 | 0.81 | PAK1 (0.38) | PAK1ULK1IP6K1ULK2 | |
| SCHEMBL16145855 | 0.81 | PAK1 (0.38) | PAK1ULK1 | |
| SCHEMBL6796913 | 0.81 | PAK1 (0.38) | PAK1ULK1IP6K1ULK2 | |
| SCHEMBL30523392 | 0.76 | PAK1 (0.91) | PAK1ULK1MAPK8LMNAHTT | |
| SCHEMBL15545184 | 0.73 | PAK1 (0.97) | PAK1ULK1LMNAHTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313422-B1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8759510-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| CN-102119167-A | nucleoside cyclic phosphates | PHARMASSET INC | 2011-07-06 | — | — | CN | disclosed |
| EP-2313422-A2 | NUCLEOSIDE CYCLICPHOSPHATES | Pharmasset, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2009152095-A2 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | PAK1 1694/4885ULK1 3228/4885IP6K1 248/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | PAK1 1694/4885ULK1 3228/4885IP6K1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.